CTOs on the Move

PharmaSeq

www.pharmaseq.com

 
PharmaSeq is a Monmouth Junction, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million
  • www.pharmaseq.com
  • 11 Deerpark Dr Ste 104
    Monmouth Junction, NJ USA 08852
  • Phone: 732.355.0100

Executives

Name Title Contact Details

Similar Companies

Mantra Bio

Mantra Bio is harnessing exosomes to deliver safe, highly targeted medicines. We are the creator of REVEALâ„¢, an exosome engineering platform combining computational biology and lab automation to generate targeted exosome vehicles (TEVs) for a broad set of therapeutic areas.

Faze Medicines

Faze Medicines is a biotechnology company pioneering therapeutics based on the groundbreaking new science of biomolecular condensates.

Champignon Brands

Champignon Brands is intent on being a global, vertically integrated producer of artisanal medicinal mushrooms and associated products. The Champignon team is focused on enhancing the health and wellness of millions of consumers who can benefit from its premium suite of organic, sustainable and non-GMO mushroom formulations. Champignon`s mushroom-derived CPG portfolio includes our flagship brand, Vitality Superteas. Our Vitality Superteas` SKUs are formulated with with the goal of revolutionizing conventional organic tea through the infusion of a proprietary blend of artisanal mushrooms with medicinal properties.

Evommune

Evommune is a clinical stage biotechnology company dedicated to the development of transformative medicines for inflammatory diseases. We are leveraging our innovative, tissue-based approach to advance insights and accelerate the development of these transformative therapies. Evommune is led by a successful and experienced leadership team focused on building a robust pipeline of unique therapies that help patients with chronic inflammatory diseases.

Fog Pharmaceuticals

FogPharma is dedicated to the creation of a new class of medicines that target human disease drivers currently considered `undruggable`.